Global Transmucosal Drug Delivery Market Research Report
- Report Code: TR 1000
- Publish Date: Upcoming
The global transmucosal drug delivery market, mainly driven by patent cliffs, increased incidence of chronic diseases, increasing competition, improving patient compliance, and huge investments made by major pharmaceutical companies, was valued at $2.91 billion in 2013, and expected to reach $4.05 billion by 2018, at a CAGR of 6.80%.
The report ‘Global Transmucosal Drug Delivery Market forecast, 2012-2018’ analyzes the market by segments such as oral (buccal and sublingual) and others (rectal, vaginal).
The North American market includes the U.S. and Canada. The key driver for the transmucosal drug delivery market in North America is the growing prevalence of chronic disease, such as migraine, diabetes, cancer pain, and asthma. Healthcare reforms in the U.S. will impact the overall drug delivery market.
Europe is the second-largest market, which consists of major European countries such as Germany, France, Italy, Spain, and the U.K. The key drivers for the transmucosal drug delivery market in Europe are the well-established pharmaceutical market, robust R&D infrastructure, and large investments in R&D in this sector.
Asia holds the third position in the transmucosal drug delivery market; however, expansion of the Asian economy, increase in disposable income, development of healthcare infrastructure, increasing penetration of health insurance, and rising prevalence of chronic diseases will drive the growth of this market.
The report also provides an extensive competitive landscaping of companies operating in transmucosal drug delivery market. The main companies operating in the transmucosal drug delivery market are BioDelivery Sciences International, Inc., Merck, NovaDel Pharma, Inc., Reckitt Benckiser Group plc., Cephalon, and CIMA Labs.
Segment and country-specific company shares, news & deals, M&A, segment-specific pipeline products, product approvals, and product recalls of the major companies have been detailed in this report.
Customization Options
Along with the market data, you can also customize the MMM assessments that meet your company’s specific needs. Customize to get comprehensive industry standard and deep-dive analysis of the following parameters:
Product Analysis
- Usage pattern (in-depth trend analysis) of the transmucosal drug delivery products (segment-wise)
- Product matrix which gives a detailed comparison of the transmucosal drug delivery product portfolio of each company mapped at country and sub-segment level
- End-user adoption rate analysis of the transmucosal drug delivery products (segment-wise and country-wise)
- Comprehensive coverage of product approvals, pipeline products, and product recalls
Epidemiology Data
- Country-specific prevalence of migraine, diabetes, cancer pain, and asthma
- Country-specific patient pool of migraine, diabetes, cancer pain, and asthma
- Disease progression (pattern analysis)
Pharmacists Forum
- Fast turn-around analysis of pharmacists’ response to market events and trends
- Pharmacist’s opinion about the transmucosal drug delivery products from different companies
- Pharmacists’ qualitative inputs on epidemiology data
- Pattern analysis of usage of drugs by physicians
Brand/Product Perception Matrix
- Comprehensive study of customers perception and behavior through our in-built social connect tool checking the virality and tonality of blogs
- Analysis of overall brand usage and familiarity and brand advocacy distribution (detractor/neutral/familiar)
Please fill in the form below to receive a free copy of the Summary of this Report
Please visit http://www.micromarketmonitor.com/custom-research-services.html to specify your custom Research Requirement
| PRODUCT TITLE | PUBLISHED | |
|---|---|---|
|
|
Oral (Buccal And Sublingual) Submarkets of this market are Drug Delivery Technology. Key Questions Answered What are market estimates and forecasts; which of Oral (Buccal And Sublingual) markets are doing well and which are not? ... |
Upcoming |
|
|
North American Transmucosal Drug Delivery Market The North American Transmucosal Drug Delivery Market is mainly driven by patent cliffs and increased incidence of chronic diseases, increasing competition and improving patient compliance,huge investment made by big pharmaceutical companies.The Market was Valued at $1.26 billion in 2013 and expected to be $1.70 billion by 2018, growing at a CAGR of 6.2%. The Transmucosal Drug Delivery Market analyzes the market by segments such as Oral (Buccal and Sublingual), and others (Rectal, Vaginal).The prominent players in the Market BioDelivery Sciences International, Inc., Merck, NovaDel Pharma, Inc., Reckitt Benckiser Group plc., Cephalon and CIMA Labs. |
Upcoming |
|
|
European Transmucosal Drug Delivery Market The European Transmucosal Drug Delivery Market is mainly driven by patent cliffs and increased incidence of chronic diseases, increasing competition and improving patient compliance,huge investment made by big pharmaceutical companies.The Market was Valued at $0.81 billion in 2013 and expected to be $1.07 billion by 2018, growing at a CAGR of 5.8%. The Transmucosal Drug Delivery Market analyzes the market by segments such as Oral (Buccal and Sublingual), and others (Rectal, Vaginal).The prominent players in the Market BioDelivery Sciences International, Inc., Merck, NovaDel Pharma, Inc., Reckitt Benckiser Group plc., Cephalon and CIMA Labs. |
Upcoming |
|
|
Asian Transmucosal Drug Delivery Market The Asian Transmucosal Drug Delivery Market is mainly driven by patent cliffs and increased incidence of chronic diseases, increasing competition and improving patient compliance,huge investment made by big pharmaceutical companies.The Market was Valued at $0.48 billion in 2013 and expected to be $0.72 billion by 2018, growing at a CAGR of 8.8%. The Transmucosal Drug Delivery Market analyzes the market by segments such as Oral (Buccal and Sublingual), and others (Rectal, Vaginal).The prominent players in the Market BioDelivery Sciences International, Inc., Merck, NovaDel Pharma, Inc., Reckitt Benckiser Group plc., Cephalon and CIMA Labs. |
Upcoming |
